Australia’s MGC Pharmaceuticals has completed the final clinical trials of their cannabis skin care line with 92 percent of participants saying they would continue using the creams they tested, Business News Western Australia reports. The products were independently tested on 90 volunteers over a three-month period by Dr. Rok Devjak at a dermatology clinic in Slovenia.
According to the report, the trials found 86 percent improvement of irritated skin, 80 percent improvement in acne-prone skin, 73 percent improvement in psoriatic plaques, and 70 percent improvement in visual appearances of dryness, redness, flaky and oily skin conditions.
The results will allow MGC Pharma to market the DermaPlus products with specific claims about its effectiveness and will likely allow the products to be labeled ‘dermatologically tested,’ in line with European Parliamentary regulations.
Nativ Segev, the firm’s co-founder and managing director, said he was “exceptionally pleased” with the test results.
“Validating the use of medicinal cannabis through rigorous clinical tests is vital to our business model and, with over 50 products still in development, these positive test results give us a glimpse into the exciting potential of our product range,” he said in a statement.
The products are expected to be available via the company website and in pharmacies throughout Europe beginning in the third quarter of this year.